Pegfilgrastim
Brand name: Neulasta
Rank #387 of 500 drugs by total cost
$24.4M
Total Cost
3,096
Total Claims
$24.4M
Total Cost
102
Prescribers
$7,874
Cost per Claim
378
Beneficiaries
3,098
30-Day Fills
$239K
Avg Cost/Provider
30
Avg Claims/Provider
About Pegfilgrastim
Pegfilgrastim (sold as Neulasta) was prescribed 3,096 times by 102 Medicare Part D providers in 2023, costing the program $24.4M. At $7,874 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 384 | Pioglitazone Hcl (Pioglitazone Hcl) | $24.8M | 1,182,614 |
| 385 | Fremanezumab-Vfrm (Ajovy Autoinjector) | $24.7M | 29,389 |
| 386 | Nitrofurantoin Monohyd/M-Cryst (Nitrofurantoin Mono-Macro) | $24.4M | 1,173,249 |
| 387 | Pegfilgrastim (Neulasta) | $24.4M | 3,096 |
| 388 | Linagliptin/Metformin Hcl (Jentadueto) | $24.3M | 33,018 |
| 389 | Ocrelizumab (Ocrevus) | $24.2M | 639 |
| 390 | Fenofibrate (Fenofibrate) | $24.2M | 670,936 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology